S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption

KalVista Pharmaceuticals (KALV) Short Interest Ratio & Short Volume

$14.14
+0.49 (+3.59%)
(As of 03/1/2024 ET)

KalVista Pharmaceuticals Short Interest Data

Current Short Volume
2,990,000 shares
Previous Short Volume
2,470,000 shares
Change Vs. Previous Month
+21.05%
Dollar Volume Sold Short
$44.13 million
Short Interest Ratio / Days to Cover
4.4
Last Record Date
February 15, 2024
Outstanding Shares
34,560,000 shares
Float Size
24,220,000 shares
Short Percent of Float
12.35%
Today's Trading Volume
501,951 shares
Average Trading Volume
1,338,890 shares
Today's Volume Vs. Average
37%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling KalVista Pharmaceuticals ?

Sign up to receive the latest short interest report for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

KALV Short Interest Over Time

KALV Days to Cover Over Time

KALV Percentage of Float Shorted Over Time


KalVista Pharmaceuticals Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
2/15/20242,990,000 shares $44.13 million +21.1%12.4%4.4 $14.76
1/31/20242,470,000 shares $38.95 million -10.5%12.9%6.1 $15.77
1/15/20242,760,000 shares $35.77 million -25.2%14.2%8.3 $12.96
12/31/20233,690,000 shares $45.20 million +5.7%18.7%11.8 $12.25
12/15/20233,490,000 shares $37.27 million -9.6%16.7%10.8 $10.68
11/30/20233,860,000 shares $32.58 million -3.5%18.2%13.4 $8.44
11/15/20234,000,000 shares $30.76 million -3.4%19.0%13.9 $7.69
10/31/20234,140,000 shares $35.15 million -10.8%17.3%14.8 $8.49
10/15/20234,640,000 shares $42.13 million +4.7%N/A16.9 $9.08
9/30/20234,430,000 shares $42.66 million +9.1%N/A16.9 $9.63
9/15/20234,060,000 shares $39.87 million +4.6%N/A19.4 $9.82
8/31/20233,880,000 shares $42.10 million -5.4%N/A19.1 $10.85
8/15/20234,100,000 shares $44.32 million +2.8%19.7%21.4 $10.81
7/31/20233,990,000 shares $40.30 million +2.3%18.3%21 $10.10
7/15/20233,900,000 shares $37.60 million +3.7%17.9%21 $9.64
6/30/20233,760,000 shares $33.84 million +0.8%17.3%18.5 $9.00
6/15/20233,730,000 shares $35.92 million +3.9%17.2%17.2 $9.63
5/31/20233,590,000 shares $35.00 million +5.0%16.5%14.6 $9.75
5/15/20233,420,000 shares $34.58 million +4.3%15.8%12.6 $10.11
4/30/20233,280,000 shares $27.98 million +17.1%14.0%11.5 $8.53
4/15/20232,800,000 shares $22.15 million +3.3%12.0%8.7 $7.91
3/31/20232,710,000 shares $21.30 million +10.2%11.6%8 $7.86
3/15/20232,460,000 shares $18.33 million +13.4%N/A7 $7.45
2/28/20232,170,000 shares $15.91 million -19.6%N/A6.3 $7.33
2/15/20232,700,000 shares $20.87 million -0.4%N/A8.6 $7.73
1/31/20232,710,000 shares $21.57 million +26.6%N/A8.9 $7.96
1/15/20232,140,000 shares $15.19 million -10.5%N/A6.7 $7.10
12/30/20222,390,000 shares $16.16 million +14.9%10.2%7.4 $6.76
12/15/20222,080,000 shares $11.90 million No Change10.4%4.7 $5.72
11/30/20222,080,000 shares $11.21 million No Change10.4%5.1 $5.39
11/15/20222,080,000 shares $10.86 million -8.8%10.4%5.1 $5.22
10/31/20222,280,000 shares $11.56 million -0.4%10.9%5.5 $5.07
10/15/20222,290,000 shares $10.44 million -10.2%10.9%6.2 $4.56
9/30/20222,550,000 shares $37.00 million +3.7%12.2%7.7 $14.51
9/15/20222,460,000 shares $36.43 million +4.7%11.8%13.2 $14.81
8/31/20222,350,000 shares $38.70 million +14.6%11.2%10.7 $16.47
8/15/20222,050,000 shares $32.41 million +8.5%9.8%7.3 $15.81
7/31/20221,890,000 shares $23.34 million +2.7%9.0%6.1 $12.35
7/15/20221,840,000 shares $22.69 million +3.4%8.7%5.7 $12.33
6/30/20221,780,000 shares $17.52 million -16.8%8.5%5.3 $9.84













KALV Short Interest - Frequently Asked Questions

What is KalVista Pharmaceuticals' current short interest?

Short interest is the volume of KalVista Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of February 15th, investors have sold 2,990,000 shares of KALV short. 12.35% of KalVista Pharmaceuticals' shares are currently sold short. Learn More on KalVista Pharmaceuticals' current short interest.

What is a good short interest ratio for KalVista Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KALV shares currently have a short interest ratio of 4.0. Learn More on KalVista Pharmaceuticals's short interest ratio.

Which institutional investors are shorting KalVista Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of KalVista Pharmaceuticals: Citadel Advisors LLC, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for KalVista Pharmaceuticals?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.35% of KalVista Pharmaceuticals' floating shares are currently sold short.

Is KalVista Pharmaceuticals' short interest increasing or decreasing?

KalVista Pharmaceuticals saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 2,990,000 shares, an increase of 21.1% from the previous total of 2,470,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is KalVista Pharmaceuticals' float size?

KalVista Pharmaceuticals currently has issued a total of 34,560,000 shares. Some of KalVista Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. KalVista Pharmaceuticals currently has a public float of 24,220,000 shares.

How does KalVista Pharmaceuticals' short interest compare to its competitors?

12.35% of KalVista Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to KalVista Pharmaceuticals: Wave Life Sciences Ltd. (2.53%), Revance Therapeutics, Inc. (14.05%), Avid Bioservices, Inc. (8.93%), Mersana Therapeutics, Inc. (5.85%), Larimar Therapeutics, Inc. (3.49%), Terns Pharmaceuticals, Inc. (11.50%), LianBio (0.54%), Arbutus Biopharma Co. (2.20%), Mereo BioPharma Group plc (2.22%), Theravance Biopharma, Inc. (19.31%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Super Micro Computer, Inc. ($5.32 billion), T-Mobile US, Inc. ($4.38 billion), General Motors ($3.76 billion), Occidental Petroleum Co. ($3.08 billion), Charter Communications, Inc. ($2.65 billion), Coinbase Global, Inc. ($2.62 billion), Tractor Supply ($2.52 billion), Moderna, Inc. ($2.19 billion), Rivian Automotive, Inc. ($1.84 billion), and Royal Caribbean Cruises Ltd. ($1.78 billion). View all of the most shorted stocks.

What does it mean to sell short KalVista Pharmaceuticals stock?

Short selling KALV is an investing strategy that aims to generate trading profit from KalVista Pharmaceuticals as its price is falling. KALV shares are trading up $0.49 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against KalVista Pharmaceuticals?

A short squeeze for KalVista Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of KALV, which in turn drives the price of the stock up even further.

How often is KalVista Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KALV, twice per month. The most recent reporting period available is February, 15 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:KALV) was last updated on 3/3/2024 by MarketBeat.com Staff